Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (22)
- Safety monitoring and information (11)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
113 result(s) found, displaying 1 to 10
-
PageInformation for applicants on requesting and preparing for pre-submission meetings for medicines and biologicals.
-
Medicine shortage alertsSerious Scarcity Substitution Instrument (SSSI) allows continuous access to Catapres (clonidine) 150 mcg tablets during an anticipated new shortage.
-
PageInformation and updates about the shortages of cyclophosphamide and ifosfamide injection.
-
Medicine shortage alertsInformation about the cyclophosphamide and ifosfamide injection shortages.
-
GuidanceGuidance on the mandatory requirements for reporting current and anticipated reportable medicine shortages and discontinuations in Australia.
-
Medicine shortage alertsThe overall supply of methylphenidate modified-release products continues to improve and stabilise.
-
PageOVERALL SUPPLY IS STABLE. THE SSSI LAPSED ON 31 MARCH 2026.
-
PagePharmaceutical companies Novo Nordisk and Eli Lilly are gradually discontinuing some of their earlier generation insulin products. Our webpage lists affected products and includes alternative options.
-
PageInformation about the shortage and the Serious Scarcity Substitution Instrument
-
FormsForms for notifying the TGA of a change in sponsorship.